Eli Lilly CEO David Ricks joins 'Squawk on the Street' to discuss the company's drug pipeline, 2025 outlook, state of the weight loss drugs market, status of the weight loss drug pill, revised ...
Eli Lilly forecasts $45 billion in 2024 revenue, a 32% growth but $400 million below Q3 guidance. Mounjaro and Zepbound expected to contribute $3.5 billion and $1.9 billion, respectively, to 2024 ...
Hosted on MSN14d
Eli Lilly Stock Faces Worst Day In Nearly 4 Years On Q4 Weight-Loss Drug Sales Miss, But Retail Bullish On 2025 ProjectionsCEO David A. Ricks attributed the shortfall to slower-than-expected growth in the U.S. incretin market, compounded by lower year-end channel inventory. Incretins like GLP-1 are used in diabetes ...
David A. Ricks, Lilly chair and CEO, will participate in a fireside chat on Tuesday, Jan. 14 at 5:15 p.m. Eastern time. A live audio webcast will be available on the "Webcasts & Presentations ...
In an episode of "The David Rubenstein Show: Peer to Peer Conversations," CEO Dave Ricks talks about how the company will begin studies this year to see if its weight-loss medicines can also be ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback